Your browser doesn't support javascript.
loading
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.
Albert, Nathalie L; Preusser, Matthias; Traub-Weidinger, Tatjana; Tolboom, Nelleke; Law, Ian; Palmer, Joshua D; Guedj, Eric; Furtner, Julia; Fraioli, Francesco; Huang, Raymond Y; Johnson, Derek R; Deroose, Christophe M; Herrmann, Ken; Vogelbaum, Michael; Chang, Susan; Tonn, Joerg-Christian; Weller, Michael; Wen, Patrick Y; van den Bent, Martin J; Verger, Antoine; Ivanidze, Jana; Galldiks, Norbert.
Afiliación
  • Albert NL; Department of Nuclear Medicine, LMU Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. nathalie.albert@med.uni-muenchen.de.
  • Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Traub-Weidinger T; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
  • Tolboom N; Department of Diagnostic and Therapeutic Nuclear Medicine, Clinic Donaustadt, Vienna Health Care Group, Vienna, Austria.
  • Law I; Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.
  • Palmer JD; Division Imaging & Oncology, University Medical Centre Utrecht, Utrecht, Netherlands.
  • Guedj E; Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Furtner J; Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Fraioli F; Institut Fresnel, Nuclear Medicine Department, APHM, CNRS, Timone Hospital, CERIMED, Aix Marseille Univ, Marseille, France.
  • Huang RY; Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.
  • Johnson DR; Institute of Nuclear Medicine, University College London (UCL), London, UK.
  • Deroose CM; Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
  • Herrmann K; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Vogelbaum M; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Chang S; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK) - University Hospital Essen, Essen, Germany.
  • Tonn JC; Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA.
  • Weller M; Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA.
  • Wen PY; Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany.
  • van den Bent MJ; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Verger A; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ivanidze J; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Galldiks N; Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Université de Lorraine, Nancy, France.
Article en En | MEDLINE | ID: mdl-38898354
ABSTRACT

PURPOSE:

To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.

METHODS:

This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).

RESULTS:

Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.

CONCLUSION:

These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12)1576-87). The information provided should be considered in the context of local conditions and regulations.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Alemania